Fucoidan-induced reduction of lipid accumulation in foam cells through overexpression of lysosome genes

Int J Biol Macromol. 2024 Apr;263(Pt 2):130451. doi: 10.1016/j.ijbiomac.2024.130451. Epub 2024 Feb 24.

Abstract

Atherosclerosis (AS) is the common basis for the onset of cardiovascular events. The lipid metabolism theory considers foam cell formation as an important marker for the initiation of AS. Fucoidan is an acidic polysaccharide that can reduce lipid accumulation in foam cells. Studies show that tea polysaccharides can be transported to lysosomes via the tubulin pathway. However, the specific mechanism of action of fucoidan on foam cells has not been extensively studied. Therefore, we further explored the mechanism of action of fucoidan and evaluated whether it could reduce lipid accumulation in foam cells by affecting the expression of lysosomal pathway-related genes and proteins. In this study, three inhibitors, CPZ, EIPA, and colchicine, were used to inhibit endocytosis, macropinocytosis, and the tubulin pathway, respectively, to study the pathways of action. Transcriptomics and proteomics analysis, as well as western blotting and qRT-PCR were used to determine the effects of fucoidan and the inhibitors on lysosomal genes and proteins. Fucoidan could enter foam cells through both endocytosis and via macropinocytosis, and then further undergo intracellular transport via the tubulin pathway. After fucoidan treatment, the expression of lysosomal pathway-related genes and proteins including LAMP2, AP3, AP4, MCOLN1, and TFEB in foam cells increased significantly (P < 0.01). However, the expression of lysosomal genes and proteins after colchicine intervention was comparable with that in the model group. Therefore, the tubulin pathway inhibited by colchicine is an important pathway for the transport and distribution of fucoidan within cells. In summary, fucoidan may be transported to lysosomes via the tubulin pathway and may enhance the expression of lysosomal genes, promoting autophagy, thereby accelerating lipid clearance in foam cells. Due to its significant lipid-lowering effect, it can be used in the clinical treatment of AS.

Keywords: Atherosclerosis; Foam cells; Fucoidan; Lysosome; Proteomics.

MeSH terms

  • Atherosclerosis* / drug therapy
  • Colchicine / metabolism
  • Foam Cells* / metabolism
  • Humans
  • Lipids / pharmacology
  • Lysosomes / metabolism
  • Polysaccharides / therapeutic use
  • Tubulin / metabolism

Substances

  • fucoidan
  • Tubulin
  • Polysaccharides
  • Lipids
  • Colchicine